Header Logo

Connection

Constantinos Wibmer to Antibodies, Neutralizing

This is a "connection" page, showing publications Constantinos Wibmer has written about Antibodies, Neutralizing.
Connection Strength

2,915
  1. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0,460
  2. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. J Virol. 2016 Nov 15; 90(22):10220-10235.
    View in: PubMed
    Score: 0,454
  3. HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS. 2015 May; 10(3):135-43.
    View in: PubMed
    Score: 0,409
  4. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
    View in: PubMed
    Score: 0,369
  5. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
    View in: PubMed
    Score: 0,154
  6. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
    View in: PubMed
    Score: 0,154
  7. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. J Virol. 2020 01 06; 94(2).
    View in: PubMed
    Score: 0,142
  8. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
    View in: PubMed
    Score: 0,106
  9. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
    View in: PubMed
    Score: 0,094
  10. Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J. 2013 Dec 02; 10:347.
    View in: PubMed
    Score: 0,093
  11. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,086
  12. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011 Nov; 85(21):11502-19.
    View in: PubMed
    Score: 0,079
  13. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011 Aug; 85(15):7719-29.
    View in: PubMed
    Score: 0,078
  14. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011 May; 85(10):4828-40.
    View in: PubMed
    Score: 0,077
  15. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathog. 2022 Apr; 18(4):e1010465.
    View in: PubMed
    Score: 0,042
  16. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
    View in: PubMed
    Score: 0,041
  17. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 03; 603(7902):679-686.
    View in: PubMed
    Score: 0,041
  18. The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin a4ß7 and promotes cellular activation and infection. Proc Natl Acad Sci U S A. 2020 12 22; 117(51):32566-32573.
    View in: PubMed
    Score: 0,038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.